|
Real-time Estimate
Cboe BZX
14:16:25 2026-09-21 EDT
|
5-day change | 1st Jan Change | ||
| 25.20 USD | +6.67% |
|
+5.31% | -5.97% |
| 08-18 | Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating | MT |
| 08-07 | Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
Company Valuation: Amphastar Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,114 | 1,354 | 2,963 | 1,785 | 1,231 | 1,005 | - | - |
| Change | - | 21.52% | 118.8% | -39.75% | -31.07% | -18.35% | - | - |
| Enterprise Value (EV) 1 | 1,114 | 1,354 | 2,963 | 2,235 | 1,231 | 1,308 | 1,189 | 1,062 |
| Change | - | 21.52% | 118.8% | -24.56% | -44.95% | 6.3% | -9.12% | -10.64% |
| P/E | 18.6x | 16.1x | 23.8x | 12.1x | 13.2x | 10.9x | 8.95x | 9.52x |
| PBR | - | - | - | 2.41x | 1.55x | 1.14x | - | - |
| PEG | - | 0.4x | 0.5x | 0.7x | -0.4x | 1.58x | 0.4x | -1.57x |
| Capitalization / Revenue | 2.55x | 2.71x | 4.6x | 2.44x | 1.71x | 1.34x | 1.28x | 1.24x |
| EV / Revenue | 2.55x | 2.71x | 4.6x | 3.05x | 1.71x | 1.75x | 1.52x | 1.31x |
| EV / EBITDA | 11.2x | 9.21x | 10.4x | 7.18x | 4.97x | 6.12x | 5.58x | 5.07x |
| EV / EBIT | 14.5x | 11.1x | 12.1x | 8.66x | 5.7x | 7.23x | 6.45x | 5.46x |
| EV / FCF | - | 20.8x | - | 13x | 10.2x | 9.62x | 9.91x | 8.36x |
| FCF Yield | - | 4.81% | - | 7.71% | 9.85% | 10.4% | 10.1% | 12% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.25 | 1.74 | 2.6 | 3.06 | 2.03 | 2.17 | 2.64 | 2.48 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 437.8 | 499 | 644.4 | 732 | 719.9 | 747.7 | 784.4 | 808.2 |
| EBITDA 1 | 99.1 | 147.1 | 283.9 | 311.1 | 247.5 | 213.9 | 213.1 | 209.7 |
| EBIT 1 | 76.9 | 121.8 | 245.8 | 258.2 | 215.9 | 180.9 | 184.4 | 194.4 |
| Net income 1 | 62.12 | 91.39 | 137.5 | 159.5 | 98.09 | 99.32 | 115.4 | 111.1 |
| Net Debt 1 | - | - | - | 450 | - | 303.4 | 184.1 | 57.6 |
| Reference price 2 | 23.29 | 28.02 | 61.85 | 37.13 | 26.78 | 23.62 | 23.62 | 23.62 |
| Nbr of stocks (in thousands) | 47,849 | 48,331 | 47,907 | 48,081 | 45,952 | 42,538 | - | - |
| Announcement Date | 3/10/22 | 2/28/23 | 2/28/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 10.88x | 1.75x | 6.12x | -.--% | 1B | |
| 32.78x | 11.92x | 24.16x | 0.6% | 1,028B | |
| 30.03x | 6.68x | 18.7x | 1.99% | 651B | |
| 33.38x | 7.81x | 16.15x | 2.6% | 466B | |
| 19.33x | 4.72x | 11.71x | 2.81% | 346B | |
| 19.72x | 5.16x | 12.79x | 3.11% | 266B | |
| 21.26x | 4.42x | 12.58x | 1.99% | 259B | |
| 24.43x | 6.42x | 11.43x | 2.62% | 208B | |
| 12.52x | 4.56x | 9.46x | 4.01% | 191B | |
| -45.4x | 6.61x | 25.81x | 2.19% | 186B | |
| Average | 15.89x | 6.00x | 14.89x | 2.19% | 360.27B | |
| Weighted average by Cap. | 23.67x | 7.72x | 17.83x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMPH Stock
- Valuation Amphastar Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
